• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments.

作者信息

Chaires J B, Herrera J E, Waring M J

机构信息

Department of Biochemistry, University of Mississippi Medical Center, Jackson 39216-4505.

出版信息

Biochemistry. 1990 Jul 3;29(26):6145-53. doi: 10.1021/bi00478a006.

DOI:10.1021/bi00478a006
PMID:2207063
Abstract

Results from a high-resolution deoxyribonuclease I (DNase I) footprinting titration procedure are described that identify preferred daunomycin binding sites within the 160 bp tyr T DNA fragment. We have obtained single-bond resolution at 65 of the 160 potential binding sites within the tyr T fragment and have examined the effect of 0-3.0 microM total daunomycin concentration on the susceptibility of these sites toward digestion by DNase I. Four types of behavior are observed: (i) protection from DNase I cleavage; (ii) protection, but only after reaching a critical total daunomycin concentration; (iii) enhanced cleavage; (iv) no effect of added drug. Ten sites were identified as the most strongly protected on the basis of the magnitude of the reduction of their digestion product band areas in the presence of daunomycin. These were identified as the preferred daunomycin binding sites. Seven of these 10 sites are found at the end of the triplet sequences 5'ATGC and 5'ATCG, where the notation AT indicates that either A or T may occupy the position. The remaining three strongly protected sites are found at the ends of the triplet sequence 5'ATCAT. Of the preferred daunomycin binding sites we identify in this study, the sequence 5'ATCG is consistent with the specificity predicted by the theoretical studies of Chen et al. [Chen, K.-X., Gresh, N., & Pullman, B. (1985) J. Biomol. Struct. Dyn. 3, 445-466] and is the very sequence to which daunomycin is observed to be bound in two recent X-ray crystallographic studies. Solution studies, theoretical studies, and crystallographic studies have thus converged to provide a consistent and coherent picture of the sequence preference of this important anticancer antibiotic.

摘要

相似文献

1
Preferential binding of daunomycin to 5'ATCG and 5'ATGC sequences revealed by footprinting titration experiments.
Biochemistry. 1990 Jul 3;29(26):6145-53. doi: 10.1021/bi00478a006.
2
Site and sequence specificity of the daunomycin-DNA interaction.柔红霉素与DNA相互作用的位点及序列特异性
Biochemistry. 1987 Dec 15;26(25):8227-36. doi: 10.1021/bi00399a031.
3
Binding of daunomycin to diaminopurine- and/or inosine-substituted DNA.柔红霉素与二氨基嘌呤和/或肌苷取代的DNA的结合。
Biochemistry. 1998 Jan 27;37(4):1033-45. doi: 10.1021/bi9716128.
4
Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains.蒽环类抗肿瘤抗生素及相关糖侧链的酶促和化学足迹分析。
Biochemistry. 1996 Jun 18;35(24):7974-82. doi: 10.1021/bi952495o.
5
Sequence selective binding of ditrisarubicin B to DNA: comparison with daunomycin.
FEBS Lett. 1989 Jul 3;250(2):323-7. doi: 10.1016/0014-5793(89)80747-1.
6
DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene.靶向人c-myc基因P2启动子的柔红霉素偶联三链形成寡核苷酸的DNA结合及抗基因活性
Nucleic Acids Res. 2004 Apr 30;32(8):2396-410. doi: 10.1093/nar/gkh527. Print 2004.
7
Biophysical chemistry of the daunomycin-DNA interaction.
Biophys Chem. 1990 Apr;35(2-3):191-202. doi: 10.1016/0301-4622(90)80008-u.
8
Characterization of preferred deoxyribonuclease I cleavage sites.优选脱氧核糖核酸酶I切割位点的表征
J Mol Biol. 1994 Feb 18;236(2):405-11. doi: 10.1006/jmbi.1994.1152.
9
Elucidation of the DNA sequence preferences of daunomycin.阐明柔红霉素的DNA序列偏好性。
Drug Des Deliv. 1988 Jul;3(2):125-51.
10
Association of anthracyclines and synthetic hexanucleotides. Structural factors influencing sequence specificity.
J Mol Recognit. 1989 Nov;2(3):132-41. doi: 10.1002/jmr.300020306.

引用本文的文献

1
Isolation, Characterization, and Anticancer Evaluation of Alkaloids from (Rubiaceae).茜草科植物生物碱的分离、表征及抗癌评估
ACS Omega. 2025 Aug 4;10(32):35719-35737. doi: 10.1021/acsomega.5c02401. eCollection 2025 Aug 19.
2
The Daunomycin: Biosynthesis, Actions, and the Search for New Solutions to Enhance Production.柔红霉素:生物合成、作用及提高产量的新解决方案探索
Microorganisms. 2024 Dec 19;12(12):2639. doi: 10.3390/microorganisms12122639.
3
DOX-DNA Interactions on the Nanoscale: In Situ Studies Using Tip-Enhanced Raman Scattering.
纳米尺度上的 DOX-DNA 相互作用:使用尖端增强拉曼散射的原位研究。
Anal Chem. 2024 Jun 4;96(22):8905-8913. doi: 10.1021/acs.analchem.3c05372. Epub 2024 May 21.
4
Design, synthesis and evaluation of the anti-breast cancer activity of 1,3-oxazolo[4,5-]pyrimidine and 1,3-oxazolo[5,4-]pyrimidine derivatives.1,3-恶唑并[4,5-]嘧啶和1,3-恶唑并[5,4-]嘧啶衍生物的抗乳腺癌活性的设计、合成与评估
RSC Med Chem. 2023 Feb 16;14(4):692-699. doi: 10.1039/d2md00377e. eCollection 2023 Apr 26.
5
In silico study of HASDI (high-affinity selective DNA intercalator) as a new agent capable of highly selective recognition of the DNA sequence.计算机模拟研究 HASDI(高亲和性选择性 DNA 嵌入剂)作为一种新的试剂,能够高度选择性地识别 DNA 序列。
Sci Rep. 2023 Apr 3;13(1):5395. doi: 10.1038/s41598-023-32595-4.
6
Inhibitory effects of anthracyclines on partially purified 5'-3' DNA helicase of Plasmodium falciparum.阿霉素对恶性疟原虫 5'-3' DNA 解旋酶的部分纯化的抑制作用。
Malar J. 2022 Jul 11;21(1):216. doi: 10.1186/s12936-022-04238-y.
7
DNA aptamer-based dual-responsive nanoplatform for targeted MRI and combination therapy for cancer.用于靶向磁共振成像及癌症联合治疗的基于DNA适配体的双响应纳米平台
RSC Adv. 2022 Jan 31;12(7):3871-3882. doi: 10.1039/d1ra08373b. eCollection 2022 Jan 28.
8
Aptamer Functionalized Upconversion Nanotheranostic Agent With Nuclear Targeting as the Highly Localized Drug-Delivery System of Doxorubicin.具有核靶向功能的适体功能化上转换纳米诊疗剂作为阿霉素的高度局部化给药系统
Front Bioeng Biotechnol. 2021 Feb 22;9:639487. doi: 10.3389/fbioe.2021.639487. eCollection 2021.
9
Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3.基于 MAGE-A3 共享肿瘤特异性肽抗原的适体靶向药物递送。
Cancer Biol Ther. 2021 Jan 2;22(1):12-18. doi: 10.1080/15384047.2020.1833156. Epub 2020 Nov 29.
10
Doxorubicin-Conjugated Innovative 16-mer DNA Aptamer-Based Annexin A1 Targeted Anti-Cancer Drug Delivery.基于阿霉素共轭创新16聚体DNA适配体的膜联蛋白A1靶向抗癌药物递送
Mol Ther Nucleic Acids. 2020 Sep 4;21:1074-1086. doi: 10.1016/j.omtn.2020.07.038. Epub 2020 Jul 31.